Loading...

Bumrungrad Hospital Public Company Limited

BUHPFPNK
Healthcare
Medical - Care Facilities
$4.85
$0.00(0.00%)

Bumrungrad Hospital Public Company Limited (BUHPF) Financial Performance & Income Statement Overview

Analyze Bumrungrad Hospital Public Company Limited (BUHPF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
1.35%
1.35%
Operating Income Growth
7.83%
7.83%
Net Income Growth
10.97%
10.97%
Operating Cash Flow Growth
22.23%
22.23%
Operating Margin
35.16%
35.16%
Gross Margin
51.08%
51.08%
Net Profit Margin
29.75%
29.75%
ROE
26.87%
26.87%
ROIC
29.33%
29.33%

Bumrungrad Hospital Public Company Limited (BUHPF) Income Statement & Financial Overview

Explore comprehensive income reports for Bumrungrad Hospital Public Company Limited BUHPF, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$6.14B$6.47B$6.41B$6.28B
Cost of Revenue$3.04B$3.26B$3.09B$3.008B
Gross Profit$3.10B$3.21B$3.32B$3.27B
Gross Profit Ratio$0.50$0.50$0.52$0.52
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$1.08B$1.14B$1.003B$1.007B
Operating Expenses$1.02B$1.09B$995.83M$1.007B
Total Costs & Expenses$4.06B$4.35B$4.09B$4.01B
Interest Income$63.39M$65.61M$73.56M$78.82M
Interest Expense$2.03M$2.05M$2.12M$2.06M
Depreciation & Amortization$255.71M$274.84M$268.95M$266.53M
EBITDA$2.40B$2.47B$2.66B$2.58B
EBITDA Ratio$0.39$0.38$0.42$0.41
Operating Income$2.08B$2.13B$2.32B$2.27B
Operating Income Ratio$0.34$0.33$0.36$0.36
Other Income/Expenses (Net)$61.35M$63.41M$71.18M$120.29M
Income Before Tax$2.14B$2.19B$2.39B$2.39B
Income Before Tax Ratio$0.35$0.34$0.37$0.38
Income Tax Expense$400.10M$278.96M$424.06M$431.55M
Net Income$1.73B$1.90B$1.96B$1.93B
Net Income Ratio$0.28$0.29$0.31$0.31
EPS$2.18$2.39$2.46$2.43
Diluted EPS$2.00$2.19$2.25$2.23
Weighted Avg Shares Outstanding$794.93M$794.91M$794.91M$794.91M
Weighted Avg Shares Outstanding (Diluted)$867.41M$867.41M$867.41M$867.41M

Over the past four quarters, Bumrungrad Hospital Public Company Limited demonstrated steady revenue growth, increasing from $6.28B in Q2 2024 to $6.14B in Q1 2025. Operating income reached $2.08B in Q1 2025, maintaining a consistent 34% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $2.40B, reflecting operational efficiency. Net income dropped to $1.73B, with EPS at $2.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;